ID   XYLT2_HUMAN             Reviewed;         865 AA.
AC   Q9H1B5; Q6UY41; Q86V00;
DT   10-MAY-2005, integrated into UniProtKB/Swiss-Prot.
DT   20-FEB-2007, sequence version 2.
DT   10-MAY-2017, entry version 125.
DE   RecName: Full=Xylosyltransferase 2;
DE            EC=2.4.2.26 {ECO:0000250|UniProtKB:Q86Y38};
DE   AltName: Full=Peptide O-xylosyltransferase 1;
DE   AltName: Full=Xylosyltransferase II;
DE            Short=XT-II;
DE            Short=XylT-II;
GN   Name=XYLT2; Synonyms=XT2; ORFNames=UNQ3058/PRO9878;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT THR-305, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Chondrosarcoma;
RX   PubMed=11099377; DOI=10.1006/jmbi.2000.4261;
RA   Goetting C., Kuhn J., Zahn R., Brinkmann T., Kleesiek K.;
RT   "Molecular cloning and expression of human UDP-D-xylose:proteoglycan
RT   core protein beta-D-xylosyltransferase and its first isoform XT-II.";
RL   J. Mol. Biol. 304:517-528(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S.,
RA   Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,
RA   Lewis L., Liao D., Mark M.R., Robbie E., Sanchez C., Schoenfeld J.,
RA   Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,
RA   Vandlen R.L., Watanabe C., Wieand D., Woods K., Xie M.-H.,
RA   Yansura D.G., Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A.D.,
RA   Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale
RT   effort to identify novel human secreted and transmembrane proteins: a
RT   bioinformatics assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   THR-305.
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   INVOLVEMENT IN PXE, VARIANT PXE ARG-801, AND VARIANTS ASN-56; LEU-115;
RP   THR-305 AND LEU-418.
RX   PubMed=16571645; DOI=10.1136/jmg.2006.040972;
RA   Schon S., Schulz V., Prante C., Hendig D., Szliska C., Kuhn J.,
RA   Kleesiek K., Gotting C.;
RT   "Polymorphisms in the xylosyltransferase genes cause higher serum XT-I
RT   activity in patients with pseudoxanthoma elasticum (PXE) and are
RT   involved in a severe disease course.";
RL   J. Med. Genet. 43:745-749(2006).
RN   [5]
RP   FUNCTION, AND INVOLVEMENT IN SOS.
RX   PubMed=26027496; DOI=10.1016/j.ajhg.2015.04.017;
RA   Munns C.F., Fahiminiya S., Poudel N., Munteanu M.C., Majewski J.,
RA   Sillence D.O., Metcalf J.P., Biggin A., Glorieux F., Fassier F.,
RA   Rauch F., Hinsdale M.E.;
RT   "Homozygosity for frameshift mutations in XYLT2 result in a spondylo-
RT   ocular syndrome with bone fragility, cataracts, and hearing defects.";
RL   Am. J. Hum. Genet. 96:971-978(2015).
CC   -!- FUNCTION: Involved in the formation of heparan sulfate and
CC       chondroitin sulfate proteoglycans (PubMed:26027496). Probably
CC       catalyzes the first step in biosynthesis of glycosaminoglycan.
CC       Transfers D-xylose from UDP-D-xylose to specific serine residues
CC       of the core protein. Initial enzyme in the biosynthesis of
CC       chondroitin sulfate and dermatan sulfate proteoglycans in
CC       fibroblasts and chondrocytes (By similarity). Its enzyme activity
CC       has not been demonstrated. {ECO:0000250|UniProtKB:Q86Y38,
CC       ECO:0000269|PubMed:26027496}.
CC   -!- CATALYTIC ACTIVITY: UDP-alpha-D-xylose + [protein]-L-serine = UDP
CC       + [protein]-3-O-(beta-D-xylosyl)-L-serine.
CC       {ECO:0000250|UniProtKB:Q86Y38}.
CC   -!- COFACTOR:
CC       Name=a divalent metal cation; Xref=ChEBI:CHEBI:60240;
CC         Evidence={ECO:0000250|UniProtKB:Q86Y38};
CC   -!- PATHWAY: Glycan metabolism; chondroitin sulfate biosynthesis.
CC   -!- PATHWAY: Glycan metabolism; heparan sulfate biosynthesis.
CC   -!- SUBUNIT: Monomer. {ECO:0000250|UniProtKB:Q86Y38}.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000250}; Single-pass type II membrane protein {ECO:0000250}.
CC       Golgi apparatus membrane {ECO:0000250}; Single-pass type II
CC       membrane protein {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9H1B5-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9H1B5-2; Sequence=VSP_013758, VSP_013759;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Expressed at higher level in
CC       kidney and pancreas. {ECO:0000269|PubMed:11099377}.
CC   -!- PTM: Contains disulfide bonds. {ECO:0000250|UniProtKB:Q86Y38}.
CC   -!- DISEASE: Spondyloocular syndrome (SOS) [MIM:605822]: A syndrome
CC       characterized by cataract, loss of vision due to retinal
CC       detachment, facial dysmorphism, facial hypotonia, normal height
CC       with disproportional short trunk, osteoporosis, immobile spine
CC       with thoracic kyphosis and reduced lumbal lordosis.
CC       {ECO:0000269|PubMed:26027496}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Pseudoxanthoma elasticum (PXE) [MIM:264800]: A
CC       multisystem disorder characterized by accumulation of mineralized
CC       and fragmented elastic fibers in the skin, vascular walls, and
CC       Burch membrane in the eye. Clinically, patients exhibit
CC       characteristic lesions of the posterior segment of the eye
CC       including peau d'orange, angioid streaks, and choroidal
CC       neovascularizations, of the skin including soft, ivory colored
CC       papules in a reticular pattern that predominantly affect the neck
CC       and large flexor surfaces, and of the cardiovascular system with
CC       peripheral and coronary arterial occlusive disease as well as
CC       gastrointestinal bleedings. {ECO:0000269|PubMed:16571645}.
CC       Note=The gene represented in this entry acts as a disease
CC       modifier. PXE patients carrying causative ABCC6 mutations,
CC       manifest a more severe disease course characterized by earlier
CC       onset, frequent skin lesions and higher organ involvement, in the
CC       presence of XYLT2 variants. {ECO:0000269|PubMed:16571645}.
CC   -!- SIMILARITY: Belongs to the glycosyltransferase 14 family. XylT
CC       subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ277442; CAC16788.1; -; mRNA.
DR   EMBL; AY358090; AAQ88457.1; -; mRNA.
DR   EMBL; BC052262; AAH52262.2; -; mRNA.
DR   CCDS; CCDS11563.1; -. [Q9H1B5-1]
DR   RefSeq; NP_071450.2; NM_022167.3. [Q9H1B5-1]
DR   UniGene; Hs.463416; -.
DR   UniGene; Hs.718822; -.
DR   ProteinModelPortal; Q9H1B5; -.
DR   BioGrid; 122081; 12.
DR   IntAct; Q9H1B5; 1.
DR   STRING; 9606.ENSP00000017003; -.
DR   CAZy; GT14; Glycosyltransferase Family 14.
DR   iPTMnet; Q9H1B5; -.
DR   PhosphoSitePlus; Q9H1B5; -.
DR   BioMuta; XYLT2; -.
DR   DMDM; 126302616; -.
DR   EPD; Q9H1B5; -.
DR   MaxQB; Q9H1B5; -.
DR   PaxDb; Q9H1B5; -.
DR   PeptideAtlas; Q9H1B5; -.
DR   PRIDE; Q9H1B5; -.
DR   DNASU; 64132; -.
DR   Ensembl; ENST00000017003; ENSP00000017003; ENSG00000015532. [Q9H1B5-1]
DR   GeneID; 64132; -.
DR   KEGG; hsa:64132; -.
DR   UCSC; uc002iqo.5; human. [Q9H1B5-1]
DR   CTD; 64132; -.
DR   DisGeNET; 64132; -.
DR   GeneCards; XYLT2; -.
DR   H-InvDB; HIX0013973; -.
DR   HGNC; HGNC:15517; XYLT2.
DR   HPA; HPA016456; -.
DR   MalaCards; XYLT2; -.
DR   MIM; 264800; phenotype.
DR   MIM; 605822; phenotype.
DR   MIM; 608125; gene.
DR   neXtProt; NX_Q9H1B5; -.
DR   OpenTargets; ENSG00000015532; -.
DR   PharmGKB; PA37974; -.
DR   eggNOG; KOG0799; Eukaryota.
DR   eggNOG; ENOG410XQ7M; LUCA.
DR   GeneTree; ENSGT00760000119183; -.
DR   HOGENOM; HOG000070086; -.
DR   HOVERGEN; HBG059443; -.
DR   InParanoid; Q9H1B5; -.
DR   KO; K00771; -.
DR   OMA; VPRHCQL; -.
DR   OrthoDB; EOG091G020K; -.
DR   PhylomeDB; Q9H1B5; -.
DR   TreeFam; TF315534; -.
DR   BioCyc; MetaCyc:HS00371-MONOMER; -.
DR   BRENDA; 2.4.2.26; 2681.
DR   Reactome; R-HSA-1971475; A tetrasaccharide linker sequence is required for GAG synthesis.
DR   SignaLink; Q9H1B5; -.
DR   UniPathway; UPA00755; -.
DR   UniPathway; UPA00756; -.
DR   GeneWiki; XYLT2; -.
DR   GenomeRNAi; 64132; -.
DR   PRO; PR:Q9H1B5; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000015532; -.
DR   CleanEx; HS_XYLT2; -.
DR   ExpressionAtlas; Q9H1B5; baseline and differential.
DR   Genevisible; Q9H1B5; HS.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0008375; F:acetylglucosaminyltransferase activity; IEA:InterPro.
DR   GO; GO:0030158; F:protein xylosyltransferase activity; TAS:Reactome.
DR   GO; GO:0030206; P:chondroitin sulfate biosynthetic process; IEA:UniProtKB-UniPathway.
DR   GO; GO:0050650; P:chondroitin sulfate proteoglycan biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0006024; P:glycosaminoglycan biosynthetic process; NAS:UniProtKB.
DR   GO; GO:0030203; P:glycosaminoglycan metabolic process; TAS:Reactome.
DR   GO; GO:0015012; P:heparan sulfate proteoglycan biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0030210; P:heparin biosynthetic process; IEA:Ensembl.
DR   InterPro; IPR003406; Glyco_trans_14.
DR   InterPro; IPR024448; XylT.
DR   Pfam; PF02485; Branch; 1.
DR   Pfam; PF12529; Xylo_C; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome; Disease mutation;
KW   Disulfide bond; Endoplasmic reticulum; Glycoprotein;
KW   Glycosyltransferase; Golgi apparatus; Membrane; Polymorphism;
KW   Reference proteome; Signal-anchor; Transferase; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN         1    865       Xylosyltransferase 2.
FT                                /FTId=PRO_0000191406.
FT   TOPO_DOM      1     15       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     16     36       Helical; Signal-anchor for type II
FT                                membrane protein. {ECO:0000255}.
FT   TOPO_DOM     37    865       Lumenal. {ECO:0000255}.
FT   CARBOHYD    122    122       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    327    327       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    683    683       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VAR_SEQ     583    638       FEPRGLPSSVHLYFYDDHFQGYLVTQAVQPSAQGPAETLEM
FT                                WLMPQGSLKLLGRSD -> LALIGTPKSVFSGTLGGYWGRW
FT                                TSLWPCSAGPGAPTSQPQWSGSTQPMWWPHLMTS (in
FT                                isoform 2).
FT                                {ECO:0000303|PubMed:12975309}.
FT                                /FTId=VSP_013758.
FT   VAR_SEQ     639    865       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:12975309}.
FT                                /FTId=VSP_013759.
FT   VARIANT      56     56       D -> N (in dbSNP:rs113835371).
FT                                {ECO:0000269|PubMed:16571645}.
FT                                /FTId=VAR_071276.
FT   VARIANT      60     60       G -> R (in dbSNP:rs739990).
FT                                /FTId=VAR_049328.
FT   VARIANT     115    115       P -> L (in dbSNP:rs748114111).
FT                                {ECO:0000269|PubMed:16571645}.
FT                                /FTId=VAR_071277.
FT   VARIANT     305    305       R -> T (in dbSNP:rs12451299).
FT                                {ECO:0000269|PubMed:11099377,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:16571645}.
FT                                /FTId=VAR_022453.
FT   VARIANT     418    418       P -> L (in dbSNP:rs72832454).
FT                                {ECO:0000269|PubMed:16571645}.
FT                                /FTId=VAR_071278.
FT   VARIANT     801    801       T -> R (in PXE; acts as a modifier of
FT                                disease severity; more frequent in
FT                                patients with a severe disease course;
FT                                dbSNP:rs6504649).
FT                                {ECO:0000269|PubMed:16571645}.
FT                                /FTId=VAR_022454.
SQ   SEQUENCE   865 AA;  96767 MW;  EF477B7C3C1B964B CRC64;
     MVASARVQKL VRRYKLAIAT ALAILLLQGL VVWSFSGLEE DEAGEKGRQR KPRPLDPGEG
     SKDTDSSAGR RGSTGRRHGR WRGRAESPGV PVAKVVRAVT SRQRASRRVP PAPPPEAPGR
     QNLSGAAAGE ALVGAAGFPP HGDTGSVEGA PQPTDNGFTP KCEIVGKDAL SALARASTKQ
     CQQEIANVVC LHQAGSLMPK AVPRHCQLTG KMSPGIQWDE SQAQQPMDGP PVRIAYMLVV
     HGRAIRQLKR LLKAVYHEQH FFYIHVDKRS DYLHREVVEL AQGYDNVRVT PWRMVTIWGG
     ASLLRMYLRS MRDLLEVPGW AWDFFINLSA TDYPTRTNEE LVAFLSKNRD KNFLKSHGRD
     NSRFIKKQGL DRLFHECDSH MWRLGERQIP AGIVVDGGSD WFVLTRSFVE YVVYTDDPLV
     AQLRQFYTYT LLPAESFFHT VLENSLACET LVDNNLRVTN WNRKLGCKCQ YKHIVDWCGC
     SPNDFKPQDF LRLQQVSRPT FFARKFESTV NQEVLEILDF HLYGSYPPGT PALKAYWENT
     YDAADGPSGL SDVMLTAYTA FARLSLHHAA TAAPPMGTPL CRFEPRGLPS SVHLYFYDDH
     FQGYLVTQAV QPSAQGPAET LEMWLMPQGS LKLLGRSDQA SRLQSLEVGT DWDPKERLFR
     NFGGLLGPLD EPVAVQRWAR GPNLTATVVW IDPTYVVATS YDITVDTETE VTQYKPPLSR
     PLRPGPWTVR LLQFWEPLGE TRFLVLPLTF NRKLPLRKDD ASWLHAGPPH NEYMEQSFQG
     LSSILNLPQP ELAEEAAQRH TQLTGPALEA WTDRELSSFW SVAGLCAIGP SPCPSLEPCR
     LTSWSSLSPD PKSELGPVKA DGRLR
//
